Citigroup Maintains Buy on Guardant Health, Raises Price Target to $215

Benzinga Newsdesk www.benzinga.com Positive 81.1%

Neg 0% Neu 0% Pos 81.1%

Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $150 to $215.